| Trial ID: | L0146 |
| Source ID: | NCT02354976
|
| Associated Drug: |
Fenofibrate
|
| Title: |
A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT02354976/results
|
| Conditions: |
Non-alcoholic Fatty Liver Disease (NAFLD|Hypertriglyceridemia
|
| Interventions: |
Drug: Placebo|Drug: Omega-3 carboxylic acid|Drug: Fenofibrate 200mg
|
| Outcome Measures: |
Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Placebo)|Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Fenofibrate)
|
| Sponsor/Collaborators: |
AstraZeneca
|
| Gender: |
All
|
| Age: |
40 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
78
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
September 1, 2015
|
| Completion Date: |
May 26, 2016
|
| Results First Posted: |
September 25, 2018
|
| Last Update Posted: |
September 25, 2018
|
| Locations: |
Research Site, G??teborg, Sweden|Research Site, Malm??, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden
|
| URL: |
https://ClinicalTrials.gov/show/NCT02354976
|
